脉络膜上曲安奈德注射治疗非感染性葡萄膜炎黄斑水肿后眼压升高的真实世界发生率和处理。

IF 2.1 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-09-10 DOI:10.1097/IAE.0000000000004677

Saif A Hamdan, Sidra Zafar, Jamie A Nassur, Yoshihiro Yonekawa, Ajay E Kuriyan, James P Dunn, Michael N Cohen, Jason Hsu, Carl D Regillo, Sunir J Garg, David Xu, Michael Klufas, Jordan D Deaner

{"title":"脉络膜上曲安奈德注射治疗非感染性葡萄膜炎黄斑水肿后眼压升高的真实世界发生率和处理。","authors":"Saif A Hamdan, Sidra Zafar, Jamie A Nassur, Yoshihiro Yonekawa, Ajay E Kuriyan, James P Dunn, Michael N Cohen, Jason Hsu, Carl D Regillo, Sunir J Garg, David Xu, Michael Klufas, Jordan D Deaner","doi":"10.1097/IAE.0000000000004677","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate the incidence of ocular hypertension (OHT) following suprachoroidal injection of triamcinolone acetonide (SCS-TA) for non-infectious uveitic macular edema.Methods: Retrospective review of eyes undergoing SCS-TA. The primary outcome was incidence of OHT (IOP > 24 mm Hg). Secondary outcomes included incidence of IOP > 30 mmHg, IOP rise ≥10 mm Hg above baseline, and treatment for OHT.Results: 76 eyes of 70 patients were treated with a mean of 1.71 (range 1-5) SCS-TA injections with an average follow-up of 7.6 (range 3.0-14.9) months. 9 eyes (11.8%) developed OHT, 4 eyes (5.3%) had IOP > 30 mmHg, and 9 eyes (11.8%) had an IOP elevation of ≥ 10 mmHg above baseline at any point after their first injection. Eyes that developed OHT were treated with topical therapy (7 eyes, mean 1.9 agents, range 1-4 agents) or close observation (2 eyes). No eyes required incisional glaucoma surgery. Eyes with history of glaucoma or OHT (7/34, 20.1%) were more likely to develop OHT versus eyes with no history (2/42, 4.8%, p = 0.03).Conclusion: In this real-world cohort, SCS-TA was associated with a low-incidence of OHT, consistent with clinical trial data. A prior history of glaucoma or OHT is a significant association for developing OHT following SCS-TA.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Incidence and Management of Ocular Hypertension Following Suprachoroidal Triamcinolone Acetonide Injection for Macular Edema in Noninfectious Uveitis.\",\"authors\":\"Saif A Hamdan, Sidra Zafar, Jamie A Nassur, Yoshihiro Yonekawa, Ajay E Kuriyan, James P Dunn, Michael N Cohen, Jason Hsu, Carl D Regillo, Sunir J Garg, David Xu, Michael Klufas, Jordan D Deaner\",\"doi\":\"10.1097/IAE.0000000000004677\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To investigate the incidence of ocular hypertension (OHT) following suprachoroidal injection of triamcinolone acetonide (SCS-TA) for non-infectious uveitic macular edema.Methods: Retrospective review of eyes undergoing SCS-TA. The primary outcome was incidence of OHT (IOP > 24 mm Hg). Secondary outcomes included incidence of IOP > 30 mmHg, IOP rise ≥10 mm Hg above baseline, and treatment for OHT.Results: 76 eyes of 70 patients were treated with a mean of 1.71 (range 1-5) SCS-TA injections with an average follow-up of 7.6 (range 3.0-14.9) months. 9 eyes (11.8%) developed OHT, 4 eyes (5.3%) had IOP > 30 mmHg, and 9 eyes (11.8%) had an IOP elevation of ≥ 10 mmHg above baseline at any point after their first injection. Eyes that developed OHT were treated with topical therapy (7 eyes, mean 1.9 agents, range 1-4 agents) or close observation (2 eyes). No eyes required incisional glaucoma surgery. Eyes with history of glaucoma or OHT (7/34, 20.1%) were more likely to develop OHT versus eyes with no history (2/42, 4.8%, p = 0.03).Conclusion: In this real-world cohort, SCS-TA was associated with a low-incidence of OHT, consistent with clinical trial data. A prior history of glaucoma or OHT is a significant association for developing OHT following SCS-TA.\",\"PeriodicalId\":54486,\"journal\":{\"name\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IAE.0000000000004677\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004677","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：探讨非感染性黄斑水肿患者在脉络膜上注射曲安奈德（SCS-TA）后眼压增高（OHT）的发生率。方法：对行SCS-TA的眼睛进行回顾性分析。主要观察指标为OHT发生率（眼压bb0 24 mm Hg）。次要结局包括IOP发生率低于30mmhg， IOP升高高于基线≥10mmhg，以及OHT治疗情况。结果：70例患者76眼，平均1.71次（范围1-5）次SCS-TA注射，平均随访7.6个月（范围3.0-14.9）。9只眼（11.8%）发生OHT， 4只眼（5.3%）IOP低于30 mmHg， 9只眼（11.8%）在首次注射后的任何时间点IOP高于基线≥10 mmHg。发生OHT的眼采用局部治疗（7眼，平均1.9剂，范围1-4剂）或密切观察（2眼）。无眼需要切口青光眼手术。有青光眼或OHT病史的眼睛（7/34,20.1%）比无青光眼病史的眼睛（2/42,4.8%,p = 0.03）更容易发生OHT。结论：在这个真实世界的队列中，SCS-TA与OHT的低发病率相关，与临床试验数据一致。既往青光眼或OHT病史是SCS-TA术后发生OHT的重要关联。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-World Incidence and Management of Ocular Hypertension Following Suprachoroidal Triamcinolone Acetonide Injection for Macular Edema in Noninfectious Uveitis.

Purpose: To investigate the incidence of ocular hypertension (OHT) following suprachoroidal injection of triamcinolone acetonide (SCS-TA) for non-infectious uveitic macular edema.

Methods: Retrospective review of eyes undergoing SCS-TA. The primary outcome was incidence of OHT (IOP > 24 mm Hg). Secondary outcomes included incidence of IOP > 30 mmHg, IOP rise ≥10 mm Hg above baseline, and treatment for OHT.

Results: 76 eyes of 70 patients were treated with a mean of 1.71 (range 1-5) SCS-TA injections with an average follow-up of 7.6 (range 3.0-14.9) months. 9 eyes (11.8%) developed OHT, 4 eyes (5.3%) had IOP > 30 mmHg, and 9 eyes (11.8%) had an IOP elevation of ≥ 10 mmHg above baseline at any point after their first injection. Eyes that developed OHT were treated with topical therapy (7 eyes, mean 1.9 agents, range 1-4 agents) or close observation (2 eyes). No eyes required incisional glaucoma surgery. Eyes with history of glaucoma or OHT (7/34, 20.1%) were more likely to develop OHT versus eyes with no history (2/42, 4.8%, p = 0.03).

Conclusion: In this real-world cohort, SCS-TA was associated with a low-incidence of OHT, consistent with clinical trial data. A prior history of glaucoma or OHT is a significant association for developing OHT following SCS-TA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.